Multimodality treatment of stage III non-small cell lung cancer: Analysis of a phase II trial using preoperative cisplatin and gemcitabine with concurrent radiotherapy

Journal of Thoracic Oncology

Volumn 4, Issue 12, 2009, Pages 1517-1523

  D'Angelillo, Rolando M ^a   Trodella, Lucio ^a   Ciresa, Marzia ^a   Cellini, Francesco ^a   Fiore, Michele ^a   Greco, Carlo ^a   Pompeo, Eugenio ^b   Mineo, Tommaso Claudio ^b   Paleari, Laura ^c   Granone, Pierluigi ^d   Ramella, Sara ^a   Cesario, Alfredo ^d,e  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Chemoradiotherapy; Gemcitabine; Locally advanced disease; Neoadjuvant therapy; Nodal clearance; Non small cell lung cancer

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ESOPHAGITIS; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PREOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 74249111654     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181b9e860     Document Type: Article

References (26)

1. Albain KS, Swann RS, Rusch VR, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). J Clin Oncol 2005; ASCO Annual Meeting Proceedings, 23(Suppl 16):7014 (abstract).
2. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
3. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-smallcell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-423.
4. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995;13:1880 -1892.
5. Trodella L, Granone P, Valente S, et al. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long term results according to downstaging. Ann Oncol 2004;15: 389-398.
6. Pezzetta E, Stupp R, Zouhair A, et al. Comparison of neoadjuvant cisplatin-based chemotherapy versus radiochemotherapy followed by resection for stage III (N2) NSCLC. Eur J Cardiothorac Surg 2005;27: 1092-1098.
7. Trodella L, Granone P, Valente S, et al. Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer. J Clin Oncol 2002;20:804-810.
8. Govindan R, Bogart J, Vokes EE. Locally advanced non-small cell lung cancer: the past, present, and future. J Thorac Oncol 2008;3:917-928.
9. D'Addario G, Felip E. On behalf of the ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO clinical. Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19(Suppl 2):ii39 -ii40.
10. Grunenwald DH, Andre F, Le Pechoux C, et al. Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer. J Thorac Cardiovasc Surg 2001;122:796-802.
11. Galetta D, Cesario A, Margaritora S, et al. Enduring challenge in the treatment of non-small cell lung cancer with clinical stage IIIB: results of a trimodality approach. Ann Thorac Surg 2003;76:1802-1808.
12. Betticher DC, Hsu Schmitz SF, Tötsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003;21:1752-1759.
13. Betticher DC, Hsu Schmitz SF, Tötsch M, et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006;94:1099-1106.
14. Uy KL, Darling G, Xu W, et al. Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer. J Thorac Cardiovasc Surg 2007; 134:188-193.
15. Park BB, Park JO, Kim H, et al. Is trimodality approach better then bimodality in stage IIIA, N2 positive non-small cell lung cancer? Lung Cancer 2006;53:323-330.
16. Kuten A, Anacak Y, Abdah-Bortnyak R, et al. Neoadjuvant radiotherapy concurrent with weekly paclitaxel and carboplatin and followed by surgery in locally advanced non-small-cell lung cancer. Am J Clin Oncol 2003;26:184-187.
17. Wirth LJ, Lucca J, Ostler P, et al. Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a phase I study. Clin Cancer Res 2003;9:1698-1704.
18. Maas KW, Phernambucq EC, Sharouni SY, et al. A phase II study of weekly docetaxel/cisplatin and concurrent radiotherapy followed by surgery in patients with stage III non-small cell lung cancer (NSCLC). J Clin Oncol, 2007 ASCO. Annu Meet Proc 2005;25(Suppl 18):18050 (abstract).
19. Shewach DS, Hahn TM, Chang E, Hertel LW, Lawrence TS. Metabolism of 2′,2′-difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994;15:3218-3223.
20. van Putten JW, Price A, van der Leest AH, Gregor A, Little FA, Groen HJ. A Phase I study of GEM with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer. Clin Cancer Res 2003;9: 72-77.
21. Galetta D, Cesario A, Margaritora S, et al. Multimodality treatment of unresectable stage III non-small cell lung cancer: interim analysis of a phase II trial with preoperative gemcitabine and concurrent radiotherapy. J Thorac Cardiovasc Surg 2006;131:314-321.
22. Schumacher A, Riesenbeck D, Braunheim M, et al. Combined modality treatment for locally advanced non-small cell lung cancer: preoperative chemoradiation does not result in a poorer quality of life. Lung Cancer 2004;44:89-97.
23. Cesario A, Ferri L, Galetta D, et al. Pre-operative pulmonary rehabilitation and surgery for lung cancer. Lung Cancer 2007;57:118-119.
24. Cesario A, Ferri L, Galetta D, et al. Post-operative respiratory rehabilitation after lung resection for non-small cell lung cancer. Lung Cancer 2007;57:175-180. (Pubitemid 47049761)
25. Ramella S, Trodella L, Mineo TC, et al. Adding ipsilateral V(20) and V(30) to conventional dosimetric constraints predicts radiation pneumonitis in stage IIIA-B NSCLC treated with combined-modality therapy. Int J Radiat Oncol Biol Phys [published ahead of print July 18, 2009] PMID: 19619955.
26. Martin J, Ginsberg RJ, Abolhoda A, et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 2001;72:1149-1154.